The impact of illicit drug use and substance abuse treatment on adherence to HAART
暂无分享,去创建一个
J. Fleishman | P. Korthuis | K. Mulvey | P. Gaist | K. Gebo | G. Chander | J. Hellinger | J. Josephs | P. L. Hicks | for the HIV Research Network
[1] D. Rumball,et al. Substance Use and Mental Health , 2008 .
[2] J. Fleishman,et al. Use of complementary and alternative medicines among a multistate, multisite cohort of people living with HIV/AIDS , 2007, HIV medicine.
[3] W. Hauck,et al. Relationship of gender, depression, and health care delivery with antiretroviral adherence in HIV-infected drug users , 2003, Journal of General Internal Medicine.
[4] Joseph Conigliaro,et al. Problem drinking and medication adherence among persons with HIV infection , 2001, Journal of General Internal Medicine.
[5] Richard D Moore,et al. High Rates of Primary Mycobacterium avium Complex and Pneumocystis jiroveci Prophylaxis in the United States , 2005, Medical care.
[6] Richard D Moore,et al. Racial and Gender Disparities in Receipt of Highly Active Antiretroviral Therapy Persist in a Multistate Sample of HIV Patients in 2001 , 2005, Journal of acquired immune deficiency syndromes.
[7] N. Horton,et al. Uptake and adherence to highly active antiretroviral therapy among HIV-infected people with alcohol and other substance use problems: the impact of substance abuse treatment. , 2004, Addiction.
[8] C. Sherbourne,et al. Substance use and mental health correlates of nonadherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. , 2003, The American journal of medicine.
[9] B. Yip,et al. Impaired Virologic Response to Highly Active Antiretroviral Therapy Associated With Ongoing Injection Drug Use , 2003, Journal of acquired immune deficiency syndromes.
[10] M. Chesney,et al. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] Sally C Morton,et al. The prevalence of alcohol consumption and heavy drinking among people with HIV in the United States: results from the HIV Cost and Services Utilization Study. , 2002, Journal of studies on alcohol.
[12] V. Johnson,et al. Consequences and Determinants of Adherence to Antiretroviral Medication: Results from Adult Aids Clinical Trials Group Protocol 370 , 2001, Antiviral therapy.
[13] R. Grant,et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users , 2002, Journal of General Internal Medicine.
[14] Richard D Moore,et al. Detrimental Effects of Continued Illicit Drug Use on the Treatment of HIV‐1 Infection , 2001, Journal of acquired immune deficiency syndromes.
[15] R. Chaisson,et al. Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy , 2001, AIDS.
[16] E. Navas,et al. Long-term outcomes of protease inhibitor-based therapy in antiretroviral treatment-naive HIV-infected injection drug users on methadone maintenance programmes. , 2001, AIDS.
[17] Susan Swindells,et al. Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection , 2000, Annals of Internal Medicine.
[18] J. Walkup,et al. Drug abuse, methadone treatment, and health services use among injection drug users with AIDS. , 2000, Drug and alcohol dependence.
[19] A. Wu,et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG Adherence Instruments , 2000, AIDS care.
[20] D. Richman,et al. Predictors of Self‐Reported Adherence and Plasma HIV Concentrations in Patients on Multidrug Antiretroviral Regimens , 2000, Journal of acquired immune deficiency syndromes.
[21] F. Hecht,et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population , 2000, AIDS.
[22] J. Moatti,et al. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment , 2000, AIDS.